Millipore Sigma Vibrant Logo

09-481 Anti-PI3 Kinase Antibody, p110α

Detect PI3 Kinase using this Anti-PI3 Kinase Antibody, p110α validated for use in WB, IP, IH, ELISA.

Anti-PI3 Kinase Antibody, p110α MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Research Category: Signaling Research Sub-Category: PI3K, Akt, & mTOR Signaling Gene Symbol: EC 2.7.1.153 , MGC142161, MGC142163, PI3K, p110-alpha UniProt Number: P42336
View Products on Sigmaaldrich.com
09-481
100 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Overview

      Replacement Information

      Special Offers

      100% Performance Guaranteed

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, RWB, IP, IHC, ELISARbAffinity PurifiedPolyclonal Antibody
      Description
      Catalogue Number09-481
      Replaces04-399
      DescriptionAnti-PI3 Kinase Antibody, p110α
      Alternate Names
      • PI3-kinase p110 subunit alpha
      • PtdIns-3-kinase p110
      • phosphatidylinositol 3-kinase, catalytic, 110-KD, alpha
      • phosphatidylinositol 3-kinase, catalytic, alpha polypeptide
      • phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform
      • phosphoinositide-3-kinase, catalytic, alpha polypeptide
      Background InformationPhosphoinositol-3-kinases (PI3 Kinase, PI3K) are a family of lipid kinases that mediate many intracellular signaling responses in both physiological and pathophysiological states. PI3 Kinase is a heteroduplex with three classes (I, II, & III) of catalytic domain. The class I PI3 Kinases are made up of a p85 regulatory protein and a p110 catalytic domain. There are 4 isoforms of the class I p110 catalytic domains. Class I(A) include α, β, γ and class I(B). They are activated downstream via receptor tyrosine kinases or G-protein coupled receptors. Once activated, PI3K generates phosphatidylinositol 3,4,5-trisphosphate (PIP3) from PIP2. It was later found that PTEN, a lipid phosphatase, acts opposite to PI3K by dephosphorylating PIP3, converting it to PIP2, thus de-activating the effects of PI3K. Increased levels of PIP3 in the cell leads to the activation of many key signaling regulators including Akt and PDK as well as calcium release. One of the primary roles of PI3K is its regulation of cell growth and cell metabolism. Both of these play a critical role in cancer as some believe that a tumor’s shift to glycolysis is due to the activation of PI3K. PI3 kinases have been linked with numerous disease states, including cancer, diabetes, allergic response, hypertension, cardiac contractility, atherosclerosis, sepsis and autoimmune/ inflammatory disorders.
      References
      Product Information
      FormatAffinity Purified
      PresentationPurified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, and 0.05% sodium azide.
      Quality LevelMQ100
      Applications
      ApplicationDetect PI3 Kinase using this Anti-PI3 Kinase Antibody, p110α validated for use in WB, IP, IH, ELISA.
      Key Applications
      • Western Blotting
      • Immunoprecipitation
      • Immunohistochemistry
      • ELISA
      Biological Information
      ImmunogenKLH-conjugated synthetic linear peptide corresponding to an internal region of class I catalytic domain of PI3 Kinase that is specific to the p110 alpha isoform.
      EpitopeInternal
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostRabbit
      SpecificityRecognizes PI3 Kinase p110α.
      Species Reactivity
      • Human
      • Rat
      Species Reactivity NotePurified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, and 0.05% sodium azide.
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryPhosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. [provided by RefSeq].
      Gene Symbol
      • EC 2.7.1.153
      • MGC142161
      • MGC142163
      • PI3K
      • p110-alpha
      Purification MethodImmunogen Affinity Purified
      UniProt Number
      UniProt SummaryFUNCTION: Phosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2.

      CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate.

      SUBUNIT STRUCTURE: Heterodimer of a p110 (catalytic) and a p85 (regulatory) subunit. Binds to IRS1 in nuclear extracts. Interacts with RUFY3 By similarity.

      INVOLVEMENT IN DISEASE: Defects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500].
      Defects in PIK3CA are associated with breast cancer [MIM:114480].
      Defects in PIK3CA are associated with ovarian cancer [MIM:167000]. Ovarian cancer is the leading cause of death from gynecologic malignancy. It is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases. These typical features relate to the biology of the disease, which is a principal determinant of outcome.
      Defects in PIK3CA may underlie hepatocellular carcinoma (HCC) [MIM:114550]. Ref.14
      PI3KCA mutations affecting exons 9 and 20 display gender- and tissue-specific patterns, thus suggesting that the different amino acid changes could exert distinct functional effects on the oncogenic properties of this enzyme. Furthermore, sexual dimorphisms and tissue specific factors might directly or indirectly influence the occurrence of PI3KCA cancer alleles.

      SEQUENCE SIMILARITIES: Belongs to the PI3/PI4-kinase family.
      Contains 1 C2 domain.
      Contains 1 PI3K/PI4K domain.
      Molecular Weight110 kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceEvaluated by western blot on Jurkat cell extract.

      Western Blotting Analysis: 0.5 µg/mL (1:2,000) dilution of this antibody detected PI3K, p110α in Jurkat cell extract.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at 2-8ºC from date of receipt.
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      09-481 04053252363818

      Documentation

      Anti-PI3 Kinase Antibody, p110α SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-PI3 Kinase Antibody, p110α Certificates of Analysis

      TitleLot Number
      Anti-PI3 Kinase, p110α - 3212770 3212770
      Anti-PI3 Kinase, p110α - 3698142 3698142
      Anti-PI3 Kinase, p110α - 3746897 3746897
      Anti-PI3 Kinase, p110α -2608744 2608744
      Anti-PI3 Kinase, p110α -2694487 2694487
      Anti-PI3 Kinase, p110α -2763759 2763759
      Anti-PI3 Kinase, p110α Polyclonal Antibody 3028859

      Brochure

      Title
      Advancing cancer research: From hallmarks & biomarkers to tumor microenvironment progression